Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening.

[1]  William L Jorgensen,et al.  Efficient drug lead discovery and optimization. , 2009, Accounts of chemical research.

[2]  Luigi Petraccone,et al.  Structure-based drug design: from nucleic acid to membrane protein targets. , 2009, Experimental and molecular pathology.

[3]  R. Dodel,et al.  The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors , 2009, Cancer.

[4]  S. Donnelly,et al.  Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response , 2009, BioFactors.

[5]  T. Lóránd,et al.  Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: current developments. , 2009, Current medicinal chemistry.

[6]  Zoe Cournia,et al.  Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. , 2009, Journal of medicinal chemistry.

[7]  Andrew G. Leach,et al.  Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. , 2009, Journal of medicinal chemistry.

[8]  L. Leng,et al.  Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions. , 2009, Biochemistry.

[9]  M. Cascella,et al.  The conformational flexibility of the carboxy terminal residues 105-114 is a key modulator of the catalytic activity and stability of macrophage migration inhibitory factor. , 2008, Biochemistry.

[10]  John O Trent,et al.  A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. , 2008, Cancer research.

[11]  L. Őrfi,et al.  MIF tautomerase inhibitor potency of α,β-unsaturated cyclic ketones , 2007 .

[12]  E. Morand,et al.  Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. , 2007, Inflammation & allergy drug targets.

[13]  V. Pavlov,et al.  Alternative Chemical Modifications Reverse the Binding Orientation of a Pharmacophore Scaffold in the Active Site of Macrophage Migration Inhibitory Factor* , 2007, Journal of Biological Chemistry.

[14]  Valentin A. Pavlov,et al.  Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity and survival improving agents in sepsis. , 2007, Journal of medicinal chemistry.

[15]  R. Bucala,et al.  Macrophage migration inhibitory factor: a probable link between inflammation and cancer. , 2007, Immunity.

[16]  P. A. Golubkov,et al.  Inactivation of the phenylpyruvate tautomerase activity of macrophage migration inhibitory factor by 2-oxo-4-phenyl-3-butynoate. , 2006, Bioorganic chemistry.

[17]  Y. Al-Abed,et al.  Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity. , 2006, Bioorganic & medicinal chemistry letters.

[18]  J. Bernhagen,et al.  MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis , 2006, Nature Reviews Drug Discovery.

[19]  Y. Fukunishi,et al.  Classification of chemical compounds by protein-compound docking for use in designing a focused library. , 2006, Journal of medicinal chemistry.

[20]  Michael Bacher,et al.  ISO-1 Binding to the Tautomerase Active Site of MIF Inhibits Its Pro-inflammatory Activity and Increases Survival in Severe Sepsis* , 2005, Journal of Biological Chemistry.

[21]  T. Lóránd,et al.  Ketone bodies affect the enzymatic activity of macrophage migration inhibitory factor. , 2005, Life sciences.

[22]  E. Morand.  New therapeutic target in inflammatory disease: macrophage migration inhibitory factor , 2005, Internal medicine journal.

[23]  J. Garai,et al.  Plant-derived anti-inflammatory compounds affect MIF tautomerase activity. , 2005, International immunopharmacology.

[24]  L. Leng,et al.  Evidence for a Role of Macrophage Migration Inhibitory Factor in Vascular Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[25]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[26]  J. Spencer,et al.  A general, Brønsted acid-catalyzed hetero-Michael addition of nitrogen, oxygen, and sulfur nucleophiles. , 2003, Organic letters.

[27]  Elias Lolis,et al.  The Tautomerase Active Site of Macrophage Migration Inhibitory Factor Is a Potential Target for Discovery of Novel Anti-inflammatory Agents* , 2002, The Journal of Biological Chemistry.

[28]  M. Orita,et al.  Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. , 2002, Current pharmaceutical design.

[29]  R. Bucala,et al.  Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. , 2002, Journal of medicinal chemistry.

[30]  R. Kleemann,et al.  Characterization of catalytic centre mutants of macrophage migration inhibitory factor (MIF) and comparison to Cys81Ser MIF. , 2001, European journal of biochemistry.

[31]  S. Yamamoto,et al.  Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. , 2001, Journal of medicinal chemistry.

[32]  J. Bernhagen,et al.  Dissection of the enzymatic and immunologic functions of macrophage migration inhibitory factor. Full immunologic activity of N-terminally truncated mutants. , 2000, European journal of biochemistry.

[33]  P. Nesvadba.  Easy Large Scale Syntheses of 2,6-DI-t-Butyl- 7-Cyano-, 7-Carboxy-and 7-Methoxycarbonyl Quinone Methides , 2000 .

[34]  Sun,et al.  Convenient acylative dealkylation of tertiary amines , 2000, The Journal of organic chemistry.

[35]  W. Johnson,et al.  A kinetic and stereochemical investigation of the role of lysine-32 in the phenylpyruvate tautomerase activity catalyzed by macrophage migration inhibitory factor. , 1999, Biochemistry.

[36]  R. Bucala,et al.  Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs. , 1999, Bioorganic & medicinal chemistry letters.

[37]  W. Johnson,et al.  Crystal structure of macrophage migration inhibitory factor complexed with (E)-2-fluoro-p-hydroxycinnamate at 1.8 A resolution: implications for enzymatic catalysis and inhibition. , 1999, Biochemistry.

[38]  R. B. Grossman.  The Art of Writing Reasonable Organic Reaction Mechanisms , 1998 .

[39]  M. Fitzgerald,et al.  Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor. , 1998, Biochemistry.

[40]  R. Kleemann,et al.  Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. , 1998, Journal of molecular biology.

[41]  Hong-Wei Sun,et al.  Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor , 1998, The EMBO journal.

[42]  I. Tanaka,et al.  Substrate specificity for isomerase activity of macrophage migration inhibitory factor and its inhibition by indole derivatives. , 1997, Journal of biochemistry.

[43]  J. David,et al.  Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[44]  N. Abe,et al.  Nucleophilic Addition to Schiff Base. II. Addition of Phenols to N-(2-Pyridylmethylene) anilines , 1971 .

[45]  J. David.  Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Bloom,et al.  Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.

[47]  R. Bucala,et al.  The Immunoregulatory Mediator Macrophage Migration Inhibitory Factor (MIF) Catalyzes a Tautomerization Reaction , 1996, Molecular medicine.